Nanocarry is developing therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases.

The company’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond.

Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.